Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyCentene allogeneic HPC coverage update | OpenPayer
    Ask Trek AI about this page
    CurrentCentenePolicy CP MP.249

    Allogeneic Hematopoietic Progenitor Cell Therapy

    Customize your policy alerts

    Sign up for Centene Policy CP MP.249 alerts

    Get alerted when Policy CP MP.249 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria for non‑Medicare Centene-affiliated health plans for allogeneic hematopoietic progenitor cell therapies including Omisirge (omidubicel) and RegeneCyte (HPC Cord Blood), and guidance for patient selection and coding.

    Policy Summary
    PayerCentene
    PolicyAllogeneic Hematopoietic Progenitor Cell Therapy
    Policy CodePolicy CP MP.249
    Change TypeAdded RegeneCyte criteriabroadened title/description
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization referencing the product-specific medical necessity criteria and include documentation of patient age, diagnosis, transplant plan, and preparative regimen.
    SourceLink
    POLICY UPDATE CHANGES

    RegeneCyte (HPC Cord Blood) criteria (Criteria II) were added to the policy.

    Removed Omisirge-specific language from the policy title and broadened policy description to include multiple allogeneic HPC products.

    Added note to refer to Medicare-specific policy MC.CP.MP.249 for Medicare criteria.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Products addressed
    >=12Min age for Omisirge
    J3590, C9399HCPCS codes
    3Studies for RegeneCyte
    Phase 3Key study type

    Medical Necessity Criteria

    Omisirge (omidubicel) — Initial coverage

    Covered when ALL of the following are met

    ALL of the following

    • Age: Member/enrollee is >= 12 years of age
    • Diagnosis of hematologic malignancies
    • Planned transplant: Member/enrollee is planned for an umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection
    • Administration: Request is for one administration post-myeloablative conditioning

    RegeneCyte (HPC Cord Blood) — Initial coverage

    Covered when ALL of the following are met

    ALL of the following

    • Planned transplant: Member/enrollee is planned for an unrelated donor hematopoietic progenitor cell transplantation procedure
    • Preparative regimen: An appropriate preparative regimen for hematopoietic and immunologic reconstitution will be used in conjunction with the transplantation procedure
    • Indication: Member/enrollee has a disorder affecting the hematopoietic system that is inherited, acquired, or resulting from myeloablative treatment

    These medical necessity criteria apply to Centene-affiliated non‑Medicare health plans only. Medicare plan criteria are excluded from this document; for Medicare-specific criteria see policy MC.CP.MP.249.

    Use of Omisirge (omidubicel) or RegeneCyte (HPC Cord Blood) that does not meet the product-specific medical necessity criteria listed in this policy — including age, diagnosis, planned transplant type, required preparative regimen, or the single administration post‑myeloablative conditioning requirement for Omisirge — is considered not medically necessary and may be denied.

    Preparative Regimens and Administration

    RegimenCoverage rationale / requirements
    Single administration post‑myeloablative conditioning (Omisirge [omidubicel])Covered when all Omisirge medical necessity criteria are met, including member/enrollee age >= 12 years, diagnosis of hematologic malignancy, planned umbilical cord blood transplantation following myeloablative conditioning, and request is for one administration post‑myeloablative conditioning.
    Unrelated‑donor hematopoietic progenitor cell transplantation with an appropriate preparative regimen (RegeneCyte, HPC Cord Blood)Covered when all RegeneCyte medical necessity criteria are met, including planned unrelated donor hematopoietic progenitor cell transplantation, use of an appropriate preparative regimen for hematopoietic and immunologic reconstitution, and a disorder affecting the hematopoietic system that is inherited, acquired, or resulting from myeloablative treatment.

    Indication and Line of Therapy

    salvage

    ANY of the following

    • Indication context: Used as part of allogeneic hematopoietic cell transplantation for treatment of hematologic malignancy or other hematopoietic disorders following myeloablative conditioning or as specified for unrelated donor transplantation

    Prior Authorization, Documentation, and Billing

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Requests must reference the applicable medical necessity criteria for the specific product (Omisirge or RegeneCyte) and align with Centene non‑Medicare plan criteria.

    • Prior authorization required — reference policy CP MP.249 medical necessity criteria
    • Affected HCPCS: J3590 (Unclassified biologics), C9399 (Unclassified biologic drugs)
    Step Therapy

    Step therapy / sequencing

    No step therapy or sequencing is specified for Omisirge or RegeneCyte. Coverage determination is made when the product‑specific medical necessity criteria are met; there is no prerequisite trial of alternative therapies required by this policy.

    Billing and Code References

    Referenced HCPCS codesHCPCS
    J3590Unclassified biologics
    C9399Unclassified or biologicals drugs
    Minimum age for Omisirge
    Minimum age>= 12 years
    ProductOmisirge (omidubicel)
    Indication contextIntended for patients with hematologic malignancies who have a planned umbilical cord blood transplantation following myeloablative conditioning

    Key Definitions

    Myeloablative conditioning (MAC)
    DefinitionMyeloablative conditioning (MAC) is a regimen using a single agent or combination of agents anticipated to destroy hematopoietic cells in the bone marrow, producing extensive pancytopenia typically within 1–3 weeks and is typically irreversible.
    Clinical effectResults in profound depletion of marrow stem cells requiring donor hematopoietic progenitor cell infusion for recovery.
    Toxicity noteCauses significant toxicity risks including prolonged pancytopenia and associated complications (e.g., infections).
    Omisirge / RegeneCyte — product definitions
    Product classAllogeneic hematopoietic progenitor cell therapy products derived from umbilical cord blood.
    Omisirge (omidubicel)A nicotinamide-modified cord blood–derived allogeneic hematopoietic progenitor cell therapy that accelerates neutrophil recovery and reduces infections; intended for patients >= 12 years with planned umbilical cord blood transplantation after MAC.

    Clinical Background

    Allogeneic hematopoietic cell transplantation uses donor hematopoietic progenitor cells to restore bone marrow function for patients with hematologic malignancies and other disorders of the hematopoietic system. Preparative regimens such as myeloablative conditioning are used to eradicate the recipient’s marrow and immune cells before infusion and are required to permit engraftment; these regimens produce profound marrow ablation and significant infection risk during the aplastic period. Omisirge and RegeneCyte are cord blood‑derived allogeneic HPC products intended to support hematopoietic reconstitution in this transplant setting and are addressed by separate, product‑specific coverage criteria in this policy.

    Policy Summary
    PayerCentene
    PolicyAllogeneic Hematopoietic Progenitor Cell Therapy
    Policy CodePolicy CP MP.249
    Change TypeAdded RegeneCyte criteriabroadened title/description
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization referencing the product-specific medical necessity criteria and include documentation of patient age, diagnosis, transplant plan, and preparative regimen.
    SourceLink
    On This Page
    Medical Necessity CriteriaPreparative Regimens and AdministrationIndication and Line of TherapyPrior Authorization, Documentation, and BillingBilling and Code ReferencesKey DefinitionsClinical Background
    Documentation Required

    Required clinical documentation

    Documentation must demonstrate patient age eligibility, diagnosis, and planned transplant regimen. Include clinical records showing: diagnosis of a qualifying hematologic malignancy or disorder of the hematopoietic system, evidence of planned myeloablative conditioning and umbilical cord blood (for Omisirge) or unrelated donor hematopoietic progenitor cell transplantation (for RegeneCyte), and the intended single administration (Omisirge) or appropriate preparative regimen (RegeneCyte).

    • Document patient age (Omisirge: ≥ 12 years)
    • Document diagnosis and indication (e.g., hematologic malignancy or inherited/acquired hematopoietic disorder)
    • Document planned transplant type and preparative regimen (myeloablative conditioning)
    • For Omisirge: planned umbilical cord blood transplantation and request for one administration post‑myeloablation
    Denial Risk

    Denial triggers

    Denial is likely if the request does not meet the listed medical necessity criteria for Omisirge or RegeneCyte. Common triggers include missing documentation of planned myeloablative conditioning or transplant type, request for off‑label use (age or indication not supported), or requests for multiple administrations when policy specifies a single administration.

    • Denial trigger: patient age < 12 years for Omisirge
    • Denial trigger: no documentation of myeloablative conditioning or planned umbilical cord blood transplantation (Omisirge)
    • Denial trigger: no documentation of unrelated donor hematopoietic progenitor cell transplantation and appropriate preparative regimen (RegeneCyte)
    • Denial trigger: request inconsistent with product‑specific administration (e.g., >1 administration for Omisirge)
    RegeneCyte (HPC, Cord Blood)An allogeneic cord blood–derived hematopoietic progenitor cell product approved for unrelated donor hematopoietic progenitor cell transplantation with an appropriate preparative regimen for hematopoietic and immunologic reconstitution.
    Intended useSupport hematopoietic reconstitution after transplantation for inherited, acquired, or myeloablative treatment–related disorders of the hematopoietic system.